Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

Affiliations

Curtis Cooper: University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Stephen Shafran: University of Alberta, Edmonton, Alberta, Canada
Susan Greenbloom: Toronto Digestive Disease Associates, Toronto, Ontario, Canada
Robert Enns: St Paul’s Hospital, University of British Columbia, Canada
John Farley: Private Practice, Vancouver, British Columbia, Canada
Nir Hilzenrat: Jewish General Hospital and McGill University, Montreal, Quebec, Canada
Kurt Williams: Royal University Hospital, Saskatoon, Saskatchewan, Canada
Magdy Elkashab: Private practice, Toronto, Ontario, Canada
Nabil Abadir: Merck Canada Inc, Kirkland, Quebec, Canada
Manuela Neuman: University of Toronto, Toronto, Ontario, Canada

Abstract

BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.

ISSN: 2291-2789 (Print); 2291-2797 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://www.hindawi.com/journals/cjgh/